Quest Diagnostics Inc. - DGX STOCK NEWS

Quest Diagnostics and the Social and Health Research Center (SAHRC) have partnered to launch the Bienestar/Neema Coordinated School Health Program to combat childhood obesity in underserved communities, particularly among Hispanic and Black populations. This initiative, recognized by the CDC and NIH, features a digitized curriculum that engages children through interactive animations. The cost of the curriculum has decreased significantly from $18,000 to under $1,000, enhancing accessibility. The program aims to initially reach over 180,000 children and their families in Texas and New Jersey, with plans to expand across the U.S.

Quest Diagnostics (NYSE: DGX) has declared a quarterly cash dividend of $0.62 per share, set to be paid on July 21, 2021. This dividend will be distributed to shareholders of record as of July 7, 2021. As a leading diagnostic information service provider, Quest's insights significantly impact health outcomes, serving one in three adult Americans. The company emphasizes the importance of its diagnostic services in improving healthcare management and patient outcomes.

Quest Diagnostics (NYSE: DGX) announced its upcoming participation at the Jefferies Virtual Healthcare Conference. CEO Steve Rusckowski will present on the company's vision and capital strategies on June 3, 2021, at 8:00 a.m. ET. The conference will be webcast live, and an archived version will be available on their investor relations page within 24 hours, accessible until July 3, 2021. Quest Diagnostics is a leader in diagnostic services, providing vital health insights and COVID-19 testing services nationwide.

Quest Diagnostics (NYSE: DGX) has announced enhancements to its COVID-19 testing services, making testing more accessible. Starting today, adults can request a $0 out-of-pocket COVID-19 test through QuestDirect™. This option is available regardless of symptoms or exposure, aligning with recent government guidelines. Quest is set to provide capacities of 300,000 tests daily, having conducted over 40 million tests since March 2020.

A Quest Diagnostics Health Trends® report indicated that the COVID-19 pandemic significantly impacted hepatitis C virus (HCV) testing and treatment. The study, in collaboration with the CDC, revealed a 59% drop in HCV antibody testing in April 2020, with treatments falling by 43% in May 2020. Despite minor rebounds, HCV diagnoses and treatments remain 40% below pre-pandemic levels. The report emphasizes the urgent need for increased HCV testing to prevent advanced disease and transmission. An estimated 2.4 million adults in the U.S. are living with HCV, highlighting ongoing healthcare challenges.

Ginkgo Bioworks has partnered with Quest Diagnostics (NYSE:DGX) to offer COVID-19 testing services for K-12 schools across the U.S. This initiative aligns with the K-12 National Testing Action Program and leverages Quest's capacity to conduct up to 300,000 tests daily. Ginkgo’s Concentric platform will facilitate easy testing management, currently supporting around 1,000 schools. Both companies aim to enhance safety in classrooms by ensuring weekly testing for students and staff, with results typically available within a day.

Quest Diagnostics (DGX), a leader in diagnostic services, will present at the BofA Securities 2021 Virtual Healthcare Conference on May 11, 2021, at 12:30 p.m. ET. Mark Guinan, Executive VP & CFO, will outline the company’s vision, goals, and capital strategies. The live webcast can be accessed on the company’s investor relations page and will be archived for later viewing until June 10, 2021. Quest Diagnostics plays a vital role in health management, serving a significant portion of adults and healthcare providers in the U.S.

Quest Diagnostics (NYSE: DGX) reported its Q1 2021 financial results, showcasing a remarkable recovery with net revenues reaching $2.72 billion, a 49.3% increase year-over-year. The diagnostic services segment contributed $2.64 billion, reflecting a 51.5% growth. Key metrics included a 375.8% surge in diluted EPS to $3.46 and operating income of $660 million, representing a 277.2% increase. The company also announced an accelerated share repurchase plan worth $1.5 billion, indicating strong cash flow and operations.

Quest Diagnostics (NYSE: DGX) and Blueprint Genetics are presenting findings at the 2021 ACMG Annual Meeting, showcasing 10 studies on genomic sequencing's role in diagnosing inherited disorders. Notable research includes mitochondrial genome analysis improving diagnosis rates, especially in mitochondrial diseases, and next-generation sequencing (NGS) techniques enhancing hearing loss testing accuracy. These advancements exemplify the collaboration's commitment to improving patient care through innovative diagnostics and broadened access to genetic insights.